An article in the New York Times this week highlights an upcoming Supreme Court case that may be of special interest to people with diabetes.
The unresolved legal question is: Are states allowed to require stricter drug warnings than the FDA requires when it approves a drug label? Or does the FDA-approved label represent an assessment of the risks and benefits of a drug that no state can legally contradict?
The plaintiff in the case, Diana Levine, lost an arm due to a reaction from the nausea drug promethazine (brand name Phenergan). But with the recent safety concerns over some diabetes drugs, especially rosiglitazone (Avandia), people with diabetes will surely be affected by the Court’s ruling.
Fans of legal documents can read Ms. Levine’s Supreme Court brief here.
This blog entry was written by Editorial Assistant Quinn Phillips.
